Evidence map›Paper›PMID 35930058›Full record

ArticleJournal of medicinal chemistry2022

Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.

Gloria Somalo-Barranco, Carme Serra, David Lyons, Hugh D Piggins, Ralf Jockers, Amadeu Llebaria

Open access · hybridAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Gloria Somalo-BarrancoUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France.
Carme SerraMCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain.
David LyonsSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, BS8 1TD Bristol, U.K.
Hugh D PigginsSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, BS8 1TD Bristol, U.K.
Ralf JockersUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France.ORCID 0000-0002-4354-1750
Amadeu LlebariaMCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain.ORCID 0000-0002-8200-4827
Centre National de la Recherche Scientifique · FRInstitute of Advanced Chemistry of Catalonia · ESUniversity of Bristol · GB

Funding

Biotechnology and Biological Sciences Research Council BB/R019223
6 · The paper itself

Abstract

Melatonin is a neurohormone released in a circadian manner with peak levels at night. Melatonin mediates its effects mainly through G protein-coupled MT

Indexed as

MelatoninReceptor, Melatonin, MT1AnimalsCircadian RhythmLigandsRatsReceptor, Melatonin, MT2Receptors, MelatoninLigandsMelatoninReceptor, Melatonin, MT1Receptor, Melatonin, MT2Receptors, Melatonin

Identifiers

PMID35930058
PMCPMC9421648
OpenAlexW4289972258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.